Prognostic Factors for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): What's Better?

Overview

Journal Endocrine

Specialty Endocrinology

Date 2017 Apr 19

PMID 28417314

Citations 3

Authors

Massimo Milione

Affiliations

Soon will be listed here.

Citing Articles

Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas.

Chen J, Liu Y, Xu K, Ren F, Li B, Sun H Front Oncol. 2022; 12:999012.

PMID: 36226064 PMC: 9549976. DOI: 10.3389/fonc.2022.999012.

Cost-effectiveness of lutetium (Lu) oxodotreotide everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden.

Palmer J, Leeuwenkamp O World J Clin Cases. 2020; 8(20):4793-4806.

PMID: 33195647 PMC: 7642527. DOI: 10.12998/wjcc.v8.i20.4793.

KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?.

Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti M, Cittadini G Endocrine. 2017; 57(3):494-502.

PMID: 28726181 DOI: 10.1007/s12020-017-1364-8.

References

Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F . Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. Endocrine. 2016; 57(3):512-517. DOI: 10.1007/s12020-016-1180-6. View

Capella C, Heitz P, Hofler H, Solcia E, Kloppel G . Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995; 425(6):547-60. DOI: 10.1007/BF00199342. View

Vercellini P, Cribiu F, Del Gobbo A, Carcangiu M, Somigliana E, Bosari S . The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions. Fertil Steril. 2013; 99(7):1974-9. DOI: 10.1016/j.fertnstert.2013.02.002. View

Nielsen J, Christiansen J, Johnsen A, Wewer U, Nielsen F . A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999; 19(2):1262-70. PMC: 116055. DOI: 10.1128/MCB.19.2.1262. View

La Rosa S, Sessa F, Capella C, Riva C, Leone B, Klersy C . Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996; 429(6):323-33. DOI: 10.1007/BF00198436. View

Falconi M, Bartsch D, Eriksson B, Kloppel G, Lopes J, OConnor J . ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012; 95(2):120-34. DOI: 10.1159/000335587. View

Panzuto F, Nasoni S, Falconi M, Corleto V, Capurso G, Cassetta S . Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005; 12(4):1083-92. DOI: 10.1677/erc.1.01017. View

Milione M, Pusceddu S, Gasparini P, Melotti F, Maisonneuve P, Mazzaferro V . Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. Cancers (Basel). 2013; 4(3):808-20. PMC: 3712706. DOI: 10.3390/cancers4030808. View

Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L . The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology. 2016; 104(1):85-93. DOI: 10.1159/000445165. View

10.

Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L . The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer. 2012; 19(2):157-66. PMC: 4716660. DOI: 10.1530/ERC-11-0308. View

11.

Del Gobbo A, Vaira V, Guerini Rocco E, Palleschi A, Bulfamante G, Ricca D . The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. J Thorac Oncol. 2014; 9(11):1656-61. DOI: 10.1097/JTO.0000000000000316. View

12.

Pape U, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M . Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008; 15(4):1083-97. DOI: 10.1677/ERC-08-0017. View

13.

Massironi S, Del Gobbo A, Cavalcoli F, Fiori S, Conte D, Pellegrinelli A . IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. Endocrine. 2017; 58(2):360-367. DOI: 10.1007/s12020-017-1249-x. View

14.

Fazio N, Milione M . Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev. 2016; 50:61-67. DOI: 10.1016/j.ctrv.2016.08.006. View